PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem
Market characteristics
Market segmentation analysis

PART 04: MARKET SIZING

Market definition
Market sizing 2018
Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

Market segmentation by application
Comparison by application
Antiviral - Market size and forecast 2018-2023
Antibacterial - Market size and forecast 2018-2023
Antifungal - Market size and forecast 2018-2023
Antiparasitic - Market size and forecast 2018-2023
Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers
Market challenges

PART 11: MARKET TRENDS

Increase in R&D of therapeutic vaccines
Increased disease diagnostic modalities

PART 12: VENDOR LANDSCAPE

Overview
Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered
Vendor classification
Market positioning of vendors
Gilead Sciences, Inc.
GlaxoSmithKline plc
Merck & Co Inc.
Pfizer Inc.
Sanofi

PART 14: APPENDIX

Research methodology
List of abbreviations
Definition of market positioning of vendors
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Application - Market share 2018-2023 (%)
Exhibit 18: Comparison by application
Exhibit 19: Antiviral - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antiviral - Year-over-year growth 2019-2023 (%)
Exhibit 21: Antibacterial - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Antibacterial - Year-over-year growth 2019-2023 (%)
Exhibit 23: Antifungal - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Antifungal - Year-over-year growth 2019-2023 (%)
Exhibit 25: Antiparasitic - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Antiparasitic - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by application
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Some of the late-stage molecules
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Therapeutic vaccines
Exhibit 44: Some of the recent POC diagnostics approvals in the US
Exhibit 45: Some of the recently approved combination therapy drugs
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Gilead Sciences, Inc. - Vendor overview
Exhibit 52: Gilead Sciences, Inc. - Business segments
Exhibit 53: Gilead Sciences, Inc. - Organizational developments
Exhibit 54: Gilead Sciences, Inc. - Geographic focus
Exhibit 55: Gilead Sciences, Inc. - Segment focus
Exhibit 56: Gilead Sciences, Inc. - Key offerings
Exhibit 57: GlaxoSmithKline plc - Vendor overview
Exhibit 58: GlaxoSmithKline plc - Business segments
Exhibit 59: GlaxoSmithKline plc - Organizational developments
Exhibit 60: GlaxoSmithKline plc - Geographic focus
Exhibit 61: GlaxoSmithKline plc - Segment focus
Exhibit 62: GlaxoSmithKline plc - Key offerings
Exhibit 63: GlaxoSmithKline plc - Key offerings
Exhibit 64: Merck & Co Inc. - Vendor overview
Exhibit 65: Merck & Co Inc. - Business segments
Exhibit 66: Merck & Co Inc. - Organizational developments
Exhibit 67: Merck & Co Inc. - Geographic focus
Exhibit 68: Merck & Co Inc. - Segment focus
Exhibit 69: Merck & Co Inc. - Key offerings
Exhibit 70: Pfizer Inc. - Vendor overview
Exhibit 71: Pfizer Inc. - Business segments
Exhibit 72: Pfizer Inc. - Organizational developments
Exhibit 73: Pfizer Inc. - Geographic focus
Exhibit 74: Pfizer Inc. - Segment focus
Exhibit 75: Pfizer Inc. - Key offerings
Exhibit 76: Sanofi - Vendor overview
Exhibit 77: Sanofi - Business segments
Exhibit 78: Sanofi - Organizational developments
Exhibit 79: Sanofi - Geographic focus
Exhibit 80: Sanofi - Segment focus
Exhibit 81: Sanofi - Key offerings
Exhibit 82: Validation techniques employed for market sizing
Exhibit 83: Definition of market positioning of vendors

Companies Mentioned

• Gilead Sciences
• Inc.
• GlaxoSmithKline plc
• Merck & Co Inc.
• Pfizer Inc.
• Sanofi